Modeling Pharmacokinetic Profiles for Assessment of Anti-Cancer Drug on a Microfluidic System

被引:8
|
作者
Guo, Yaqiong [1 ,2 ]
Deng, Pengwei [1 ,2 ]
Chen, Wenwen [1 ,2 ]
Li, Zhongyu [1 ,3 ]
机构
[1] Chinese Acad Sci, Dalian Inst Chem Phys, Div Biotechnol, CAS Key Lab Separat Sci Analyt Chem, Dalian 116023, Peoples R China
[2] Univ Chinese Acad Sci, Beijing 100190, Peoples R China
[3] Dalian Minzu Univ, Coll Life Sci, Dalian 116600, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
microfluidics; intestine; drug; pharmacokinetic (PK) profile; CHIP; METABOLISM; ORGANS; TOXICITY; PLATFORM; TISSUES; CELLS;
D O I
10.3390/mi11060551
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The pharmacokinetic (PK) properties of drug, which include drug absorption and excretion, play an important role in determining the in vivo pharmaceutical activity. However, current in vitro systems that model PK profiles are often limited by the in vivo-like concentration profile of a drug. Herein, we present a perfused and multi-layered microfluidic chip system to model the PK profile of anti-cancer drug 5-FU in vitro. The chip device contains two layers of culture channels sandwiched by a porous membrane, which allows for drug exposure and diffusion between the two channels. The integration of upper intestine cells (Caco-2) and bottom targeted cells within the device enables the generation of loading and clearance portions of a PK curve under peristaltic flow. Fluorescein as a test molecule was initially used to generate a concentration-time curve, investigating the effects of parameters of flow rate, administration time, and initial concentration on dynamic drug concentration profiles. Furthermore, anti-cancer drug 5-FU was performed to assess its pharmaceutical activity on target cells (human lung adenocarcinoma cells or human pulmonary alveolar epithelial cells) using different drug administration regimens. A dynamic, in vivo-like 5-FU exposure refers to PK profile regimen, led to generate a lower drug concentration (dynamically fluctuate from 0 to 1 mu g/mL affected by absorption) compared to the constant exposure. Moreover, the PK profile regimen alleviates the drug-induced cytotoxicity on target cells. These results demonstrate the feasibility of determining the PK profiles using this microfluidic system with in vivo-like drug administration regimens. This established system may provide a powerful platform for the prediction of drug safety and effectiveness in the pharmaceutical research.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Anti-cancer drug - Preface
    Bergmann-Leitner, ES
    CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (19)
  • [22] Lipophilic Modification of an Anti-Cancer Stem Cell Agent Improves Pharmacokinetic and Anti-Cancer Properties
    Morla, Shravan
    Afosah, Daniel K.
    O'Hara, Connor
    Boothello, Rio
    Patel, Bhaumik B.
    Sakagami, Masahiro
    Desai, Umesh R.
    FASEB JOURNAL, 2019, 33
  • [23] Pharmaceutical and Pharmacokinetic Aspects of Nanoformulation Based Drug Delivery Systems for Anti-cancer Drugs
    Singh, Arun Kumar
    Bahadur, Shiv
    Yadav, Deepika
    Dabas, Hunny
    CURRENT PHARMACEUTICAL DESIGN, 2023, 29 (24) : 1896 - 1906
  • [24] Progress and perspective of microneedle system for anti-cancer drug delivery
    Li, Dongdong
    Hu, Doudou
    Xu, Hongxia
    Patra, Hirak K.
    Liu, Xiangrui
    Zhou, Zhuxian
    Tang, Jianbin
    Slater, Nigel
    Shen, Youqing
    BIOMATERIALS, 2021, 264
  • [25] Assessment of dihydropyrimidinone-based nanocomposites as multifunctional anti-cancer drug
    Thangamani, S.
    Mahendran, Hema Priya
    Bhattacharjee, Rama Ranjan
    Jeyaraj, Sankarganesh
    Mohanta, Kallol
    MATERIALS ADVANCES, 2021, 2 (10): : 3385 - 3393
  • [26] PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS FOR ANTI-CANCER DRUGS
    CHEN, HSG
    GROSS, JF
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1979, 2 (02) : 85 - 94
  • [27] Evaluation of in vivo pharmacokinetic study of the anti-cancer drug imatinib using silkworms as an animal model
    Yasu, Takeo
    Matsumoto, Yasuhiko
    Sugita, Takashi
    DRUG DISCOVERIES AND THERAPEUTICS, 2024, 18 (04): : 245 - 248
  • [28] Valproic acid as anti-cancer drug
    Michaelis, Martin
    Doerr, Hans Wilhelm
    Cinatl, Jindrich, Jr.
    CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (33) : 3378 - 3393
  • [29] MACROMOLECULE ANTI-CANCER DRUG CONJUGATES
    KATO, Y
    HARA, T
    JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN, 1983, 41 (12) : 1135 - 1142
  • [30] Mitosis as an anti-cancer drug target
    Anna-Leena Salmela
    Marko J. Kallio
    Chromosoma, 2013, 122 : 431 - 449